lucarista /
16 December 2016Medtech

Roche terminates diagnostics agreement with Pacific Biosciences

Roche has terminated its commercialisation and licensing agreement with Pacific Biosciences for the development and supply of diagnostic products.

The agreement was signed in 2013 but provides the option for Roche to terminate the deal for any reason with 60 days' notice.  Following the termination, Roche will retain some non-exclusive rights to certain products which were already purchased from Pacific Biosciences, but will have no rights to single molecule, real-time technology.  Michael Hunkapiller, CEO of Pacific Biosciences, said: “The clinical research and sequencing market and regulatory environment have evolved during the three years since we entered into this agreement with Roche.

"While we are disappointed with Roche’s decision to terminate the agreement, we are already familiar with this market and Roche’s decision does not significantly change our near-term plans for expanding our business to address this market.”

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at